Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZTZMD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BAY-943
|
|||||
| Synonyms |
BAY-943; VIP943
Click to Show/Hide
|
|||||
| Organization |
Bayer (Top20 MNC) (Originator) (No Rights);Vincerx Pharma
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
6.3
|
|||||
| Antibody Name |
Anti-CD123 antibody
|
Antibody Info | ||||
| Antigen Name |
Interleukin-3 receptor subunit alpha (IL3RA)
|
Antigen Info | ||||
| Payload Name |
Proprietary BAY-943 spindle protein inhibitor
|
Payload Info | ||||
| Therapeutic Target |
kinesin spindle protein (KSP)
|
Target Info | ||||
| Linker Name |
Lysine-linked legumain-cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Acute lymphoblastic leukemia |
1 Trials
|
||||||||
| Acute myeloid leukaemia |
1 Trials
|
||||||||
| Myelodysplastic syndrome |
1 Trials
|